ClinicalTrials.gg
CompletedNCT03181893Updated Sep 14, 2023Results posted

A Study In Adults With Moderate To Severe Dermatomyositis

A Phase 2 interventional study of PF-06823859 low and Placebo Arm in Dermatomyositis, sponsored by Pfizer. Completed at 41 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.

Enrollment
21st of 73
75 · median 25
Started
2018
with 3 others
Phase 2
31 of 94
5 open now
Registered
42nd of 94
by date
Lead sponsor
4 of 94
Pfizer

Among the 94 studies in Dermatomyositis with a site in United States, this one is the 21st largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2018, is one of 31 in phase 2, and was the 42nd registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Dermatomyositis with a site in United States, or all of them as a file.
02

Study summary

A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

03

Conditions studied

  • Dermatomyositis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Patients with Skin Predominant Activity:

  • Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (eg, ).
  • Confirmation of DM by the investigator and two of the following:

    1. Gottron's papules;
    2. Gottron's sign;
    3. Heliotrope eruption;
    4. Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;
    5. Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;
    6. Positive DM serology -
  • Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study.
  • Willing to provide 8 during the course of the research study

Inclusion Criteria for Patients with Muscle Predominant Activity:

  • MMT-8 ≤136/150 and PhGA, VAS ≥3 cm (0-10 cm) by visual analog scale (VAS)
  • Sum of PhGA, VAS, PtGA, and extramuscular global assessment VAS scores is ≥10 cm (0-10 cm) VAS for each.

    • Participant has failed at least two or more adequate courses of an agent or immunomodulatory agent, including IVIG, at a dose known to be effective for rheumatologic diseases.

Exclusion Criteria for Patients with Skin Predominant Activity:

  • Investigator site staff or members of their family.
  • Acute and Chronic present medical conditions
  • Intake of greater than 15 mg of prednisone or equivalent per day
  • Pregnant or breastfeeding females. Fertile men and women who will not comply with the use of 2 effective methods as per the research protocol
  • Have required management of acute or chronic infections
  • Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits.
  • lab abnormalities
  • Any health condition that may be worsened by immunosuppression

Exclusion Criteria for Patients with Muscle Predominant Activity:

Similar to patients with skin predominant activity; Intake of >20 mg oral prednisone/day, or equivalent

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Placebo comparator
    Placebo ARM

    Drug: Placebo Arm

  • Experimental
    PF-06823859 ARM high

    Drug: PF-06823859 high

  • Experimental
    PF-06823859 ARM low

    Drug: PF-06823859 low

Interventions

  • A humanized immunoglobulin neutralizing antibody

  • DrugPlacebo Arm

    Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid

  • A humanized immunoglobulin neutralizing antibody

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)

    The treatment effect was defined as the difference (mean chg from baseline at Week12 in the active treatment group minus that in the placebo group) in the mean change of CDASI activity score from baseline at Week 12. The score (range: 0-100) consists of the extent score (ES), Gottorn hands score (GHS), peringual score (PS) and allopecia score (AS). ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

    Time frame: Baseline and Week 12

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3)

    Adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Up to Week 40

  3. Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)

    Hemoglobin(HGB),hematocrit,erythrocytes(ery.),HDL cholesterol(chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery.(%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular(EMC) volume,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN; leukocytes(leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes(lym.), lym./leu.(%),neutrophils (neu.), neu./leu.(%), protein,albumin\<0.8\*LLN,\>1.2\*ULN;basophils(bas.), bas./leu.(%), eosinophils(eos.), eos./leu., monocytes(mon.), mon./leu.(%), urate\>1.2\*ULN;bilirubin (total, direct,indirect)\>1.5\*ULN;aspartate/alanine aminotransferase,gamma glutamyl transferase,lactate dehydrogenase,alkaline phosphatase\>3.0\*ULN;urea nitrogen,creatinine,triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones,protein, HGB,urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.

    Time frame: Up to Week 40

  4. Number of Participants With Vital Sign Abnormalities (Stage 3)

    Abnormality in vital signs: Sitting pulse rate \<40 beats per minute (bpm) to \>120 bpm, sitting diastolic blood pressure (DBP) \< 50 millimeter of mercury (mmHg), sitting systolic blood pressure (SBP) \<90 mmHg.

    Time frame: Baseline up to Week 40

  5. Number of Participants With Electrocardiogram (ECG) Abnormalities (Stage 3)

    ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.

    Time frame: Baseline up to Week 40

Secondary outcomes

  1. Number of Participants With TEAEs and SAEs (Stage 1 and Stage 2)

    AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 28 that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Up to Week 28

  2. Number of Participants With TEAEs and SAEs (Amended Stage 2)

    AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Up to Week 40

  3. Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2)

    HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.

    Time frame: Up to Week 28

  4. Number of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2)

    HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.

    Time frame: Up to Week 40

  5. Number of Participants With Vital Sign Abnormalities (Stage 1 and Stage 2)

    Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.

    Time frame: Up to Week 28

  6. Number of Participants With Vital Sign Abnormalities (Amended Stage 2)

    Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.

    Time frame: Up to Week 40

  7. Number of Participants With ECG Abnormalities (Stage 1 and Stage 2)

    ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.

    Time frame: Up to Week 28

  8. Number of Participants With ECG Abnormalities (Amended Stage 2)

    ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.

    Time frame: Up to Week 40

  9. Change From Baseline in CDASI Activity Score at at All Scheduled Timepoints Through Week 12 (Stage 1, Stage 2 and Amended Stage 2)

    The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

    Time frame: Baseline, Week 1, Week 4, and Week 8 (except for Week 12 which is a primary outcome measure)

  10. Change From Baseline in CDASI Activity Score at All Scheduled Timepoints Through Week 12 (Stage 3)

    The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8,12 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8, 12 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

    Time frame: Baseline, Week 1, Week 4, Week 8 and Week 12

  11. Absolute Values of CDASI Activity Score at All Scheduled Timepoints Through Week 12 (All Stages)

    The CDASI activity score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

    Time frame: Baseline, Week 1, Week 4, Week 8 and Week 12

  12. Absolute Values of CDASI Damage Score at All Scheduled Timepoints Through Week 12 (All Stages)

    The Damage Score (DS) was calculated as a sum of the total poilkiloderma score (POLS), total calcinosis score (CALS) and Gotorn's hands damage score (GHDS). The POLS characterizes specific dispigmentation in the particulal area and calcinosis score characterizes calcification of the skin in the particular area. The POLS and the CALS are summed up over 15 individual areas in the body and each of them has range 0-15. The GHDS has the range 0-2 so that the DS has the range 0-32. Higher scores indicate greater disease severity.

    Time frame: Baseline, Week 1, Week 4, Week 8 and Week 12

  13. Absolute Values for Total Improvement Score (TIS) at Week 12 and Intermediate Scheduled Time Points (Stage 3)

    The TIS was the sum of all 6 improvement scores where higher score indicates worse status (PhGA \[from the MDAAT, 0-20 scale\], PtGA \[0-10 scale\], MMT \[0-35 scale\], HAQ-DI \[0-10 scale\], muscle enzymes \[0-7.5 scale\], and extramuscular global assessment \[0-20 scale\]) associated with the change in each core set measure. A total improvement score between 0 and 100 corresponded to the degree of improvement, with higher scores corresponding to a greater degree of improvement: of ≥20 represented minimal improvement, a score of ≥40 represented moderate improvement, and a score of ≥60 represented major improvement.

    Time frame: Week 4, Week 8 and Week 12

  14. Change From Baseline in the Core Set Measures (CSM) of the TIS (Global Disease Activity [PhGA] and Extramuscular Global Assessment [EmGA]) (Stage 3)

    PhGA: assessment of the severity of disease by the physician. The physician used the visual analog scale and put a mark on 0 cm (best) -10 cm (worst) scale where higher score indicated worse status. EmGA: overall evaluation of disease activity in all extramuscular systems using visual analog scale 0 cm (best) -10 cm (worst) scale where higher score indicated worse status.

    Time frame: Baseline, Week 4, Week 8 and Week 12

  15. Change From Baseline in the CSM of the TIS (PtGA) (Stage 3)

    PtGA: assessment of the severity of disease by the participant/participant's guardian, using a visual analog scale from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.

    Time frame: Baseline, Week 4, Week 8 and Week 12

  16. Change From Baseline in the CSM of the TIS (MMT8 and HAQ01-HAQ-DI) (Stage 3)

    Manual Muscle Testing-8 designated muscle groups (MMT-8): was a set of 8 designated muscles tested unilaterally generally on right side (left side used unless right side cannot be used). Potential score range was from 0 to 80, where higher scores denoted better health status. HAQ-DI: contained eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.

    Time frame: Week 4, Week 8 and Week 12

  17. Change From Baseline in the CSM of the TIS (Aldolase and Creatine Kinase) (Stage 3)

    The LS mean (with 90% CI) of CSM of the TIS (aldolase and creatine kinase) at weeks 4, 8, 12 were presented.

    Time frame: Baseline, Week 4, Week 8 and Week 12

07

Results

Posted Sep 14, 2023

Participant flow

Baseline to Week 12 (All Stages)
Participant flow — Baseline to Week 12 (All Stages)
Milestone(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Started10221532110399
Completed9201532110399
Not completed12000000000
Withdrew: Withdrawal by subject01000000000
Withdrew: Adverse event11000000000
Weeks 12-24 (Amended Stage 2, Stage 3)
Participant flow — Weeks 12-24 (Amended Stage 2, Stage 3)
Milestone(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Started000002110399
Completed00000219288
Not completed00000001111
Withdrew: Other00000001100
Withdrew: Withdrawal by subject00000000010
Withdrew: Adverse event00000000001

Outcome measures

PrimaryChange From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)

The treatment effect was defined as the difference (mean chg from baseline at Week12 in the active treatment group minus that in the placebo group) in the mean change of CDASI activity score from baseline at Week 12. The score (range: 0-100) consists of the extent score (ES), Gottorn hands score (GHS), peringual score (PS) and allopecia score (AS). ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

Time frame:
Baseline and Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)
Units on a scale(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)-3.44 ± 5.270-19.62 ± 9.1405.00-17.40 ± 9.290-26.00 ± 7.937-3.00 ± 8.4853.00-16.40 ± 5.835-15.33 ± 6.028
Statistical analysis
  • (Stage 1) Placebo vs PF-06823859 600 mg IV (Stage 1) · LANCOVA-P model · p = <0.0001 · Mean difference (final values): -14.82 · 90% CI -20.26 to -9.37
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3)

Adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3)
Participants(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
TEAEs78
SAEs02
PrimaryNumber of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)

Hemoglobin(HGB),hematocrit,erythrocytes(ery.),HDL cholesterol(chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery.(%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular(EMC) volume,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN; leukocytes(leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes(lym.), lym./leu.(%),neutrophils (neu.), neu./leu.(%), protein,albumin\<0.8\*LLN,\>1.2\*ULN;basophils(bas.), bas./leu.(%), eosinophils(eos.), eos./leu., monocytes(mon.), mon./leu.(%), urate\>1.2\*ULN;bilirubin (total, direct,indirect)\>1.5\*ULN;aspartate/alanine aminotransferase,gamma glutamyl transferase,lactate dehydrogenase,alkaline phosphatase\>3.0\*ULN;urea nitrogen,creatinine,triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones,protein, HGB,urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)
Participants(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)01
PrimaryNumber of Participants With Vital Sign Abnormalities (Stage 3)

Abnormality in vital signs: Sitting pulse rate \<40 beats per minute (bpm) to \>120 bpm, sitting diastolic blood pressure (DBP) \< 50 millimeter of mercury (mmHg), sitting systolic blood pressure (SBP) \<90 mmHg.

Time frame:
Baseline up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities (Stage 3)
Participants(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Sitting SBP Value <90 mmHg00
Sitting DBP Value <50 mmHg00
Sitting Pulse Rate Value <40 bpm00
Sitting Pulse Rate Value >120 bpm00
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities (Stage 3)

ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.

Time frame:
Baseline up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities (Stage 3)
Participants(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
PR Interval Aggregate Value >=300 msec00
QRS Duration Aggregate Value >=200 msec00
QT Interval Aggregate Value >=500 msec00
QTcF Interval Aggregate 450<=Value<480 msec01
QTcF Interval Aggregate 480<=Value<500 msec10
QTcF Interval Aggregate Value >=500 msec00
PR %Chg >=25% or >=50%00
QRS Duration %Chg >=25% or >=50%00
30<=QTcF Chg (msec)<6000
QTcF Chg (msec) >=6001
SecondaryNumber of Participants With TEAEs and SAEs (Stage 1 and Stage 2)

AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 28 that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and SAEs (Stage 1 and Stage 2)
Participants(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV
TEAEs820153
SAEs12000
SecondaryNumber of Participants With TEAEs and SAEs (Amended Stage 2)

AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. AEs included both serious (if occurred) and all non-serious adverse events. TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and SAEs (Amended Stage 2)
Participants(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
TEAEs1183
SAEs0000
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2)

HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2)
Participants(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2)00000
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2)

HGB,hematocrit,ery.,HDL chl.\<0.8\*LLN;ret., ret./ery. (%)\<0.5\*LLN,\>1.5\*ULN;EMC volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leu.,glucose\<0.6\*LLN,\>1.5\*ULN;lym., lym./leu.(%), neu., neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;bas., bas./leu.(%), eos., eos./leu., mon., mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20. Clinical significance of laboratory parameters was determined at the investigator's discretion.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2)
Participants(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Number of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2)0000
SecondaryNumber of Participants With Vital Sign Abnormalities (Stage 1 and Stage 2)

Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities (Stage 1 and Stage 2)
Participants(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV
Sitting SBP Value <90 mmHg01000
Sitting DBP Value <50 mmHg00000
Sitting Pulse Rate Value <40 bpm00000
Sitting Pulse Rate Value >120 bpm00000
SecondaryNumber of Participants With Vital Sign Abnormalities (Amended Stage 2)

Abnormality in vital signs: Sitting pulse rate \<40 bpm to \>120 bpm, sitting DBP \< 50 mmHg, sitting SBP \<90 mmHg.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities (Amended Stage 2)
Participants(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Sitting SBP Value <90 mmHg0000
Sitting DBP Value <50 mmHg0000
Sitting Pulse Rate Value <40 bpm0000
Sitting Pulse Rate Value >120 bpm0000
SecondaryNumber of Participants With ECG Abnormalities (Stage 1 and Stage 2)

ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With ECG Abnormalities (Stage 1 and Stage 2)
Participants(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV
PR Interval Aggregate Value >=300 msec00000
QRS Duration Aggregate Value >=200 msec00000
QT Interval Aggregate Value >=500 msec00000
QTcF Interval Aggregate 450<=Value<480 msec31010
QTcF Interval Aggregate 480<=Value<500 msec00000
QTcF Interval Aggregate Value >=500 msec01000
PR %Chg >=25% or >=50%00000
QRS Duration %Chg >=25% or >=50%00000
30<=QTcF Chg (msec)<6000000
QTcF Chg (msec) >=6001000
SecondaryNumber of Participants With ECG Abnormalities (Amended Stage 2)

ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>=30, increase from baseline \>=60; 2) Pulse rate (PR) (msec): \>=300, change from baseline (Chg) \>=25% or 50%; 3) QT (msec): \>=500; 4) QRS (msec): \>=200, Chg \>=25% or 50%. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With ECG Abnormalities (Amended Stage 2)
Participants(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
PR Interval Aggregate Value >=300 msec0000
QRS Duration Aggregate Value >=200 msec0000
QT Interval Aggregate Value >=500 msec0000
QTcF Interval Aggregate 450<=Value<480 msec1030
QTcF Interval Aggregate 480<=Value<500 msec0000
QTcF Interval Aggregate Value >=500 msec0000
PR %Chg >=25% or >=50%0000
QRS Duration %Chg >=25% or >=50%0000
30<=QTcF Chg (msec)<601010
QTcF Chg (msec) >=600000
SecondaryChange From Baseline in CDASI Activity Score at at All Scheduled Timepoints Through Week 12 (Stage 1, Stage 2 and Amended Stage 2)

The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

Time frame:
Baseline, Week 1, Week 4, and Week 8 (except for Week 12 which is a primary outcome measure)
Reported as:
Mean · Units on a scale
Change From Baseline in CDASI Activity Score at at All Scheduled Timepoints Through Week 12 (Stage 1, Stage 2 and Amended Stage 2)
Units on a scale(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Week 1-2.60 ± 4.326-19.62 ± 9.1401.00-9.80 ± 12.174-2.33 ± 1.528-6.50 ± 6.3640.00-8.70 ± 5.638-6.67 ± 2.517
Week 4-2.44 ± 8.126-12.00 ± 10.2773.00-11.20 ± 10.986-15.00 ± 7.550-3.00 ± 7.071-1.00-14.40 ± 7.648-14.00 ± 2.000
Week 8-4.22 ± 6.942-17.19 ± 9.5954.00-14.20 ± 5.020-18.67 ± 10.066-2.50 ± 7.778-2.00-17.80 ± 7.540-14.00 ± 4.000
SecondaryChange From Baseline in CDASI Activity Score at All Scheduled Timepoints Through Week 12 (Stage 3)

The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8,12 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8, 12 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints. The score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

Time frame:
Baseline, Week 1, Week 4, Week 8 and Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in CDASI Activity Score at All Scheduled Timepoints Through Week 12 (Stage 3)
Units on a scale(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Week 1-2.00 ± 3.808-2.11 ± 2.522
Week 4-3.78 ± 5.333-5.11 ± 5.555
Week 8-5.00 ± 7.382-7.78 ± 6.667
Week 12-5.89 ± 8.177-8.56 ± 7.923
SecondaryAbsolute Values of CDASI Activity Score at All Scheduled Timepoints Through Week 12 (All Stages)

The CDASI activity score (range: 0-100) consists of the ES, GHS, PS and AS. ES (range: 0-90) was obtained by summing up scores for the total erythema (ER \[0-45\], redness of the skin or mucous membranes), scaling (SC \[0-30\], peeling of the skin) and erosion/ulceration (EU \[0-15\], presence of the deeper wound). Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body. GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1). PS (0-2) characterizes abnormalities around nails. The AS (0-1) characterizes hair loss. Higher scores indicate greater disease severity.

Time frame:
Baseline, Week 1, Week 4, Week 8 and Week 12
Reported as:
Mean · Units on a scale
Absolute Values of CDASI Activity Score at All Scheduled Timepoints Through Week 12 (All Stages)
Units on a scale(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Baseline31.50 ± 11.75033.23 ± 10.32323.0028.60 ± 9.01737.00 ± 9.64426.00 ± 5.65737.0035.40 ± 13.22630.00 ± 7.93717.22 ± 11.59512.56 ± 8.095
Week 128.90 ± 12.98227.68 ± 8.96224.0018.80 ± 6.53534.67 ± 9.71319.50 ± 0.70737.0026.70 ± 12.66723.33 ± 9.01815.22 ± 9.84610.44 ± 6.894
Week 428.11 ± 16.13621.23 ± 11.18226.0017.40 ± 2.40822.00 ± 12.49023.00 ± 1.41436.0021.00 ± 10.67716.00 ± 9.53913.44 ± 8.8197.44 ± 5.503
Week 826.33 ± 13.89215.29 ± 6.15727.0014.40 ± 5.85718.33 ± 5.50823.50 ± 2.12135.0017.60 ± 10.89516.00 ± 11.26912.22 ± 10.8834.78 ± 4.116
Week 1227.11 ± 14.90312.86 ± 5.87628.0011.20 ± 4.81711.00 ± 3.46423.00 ± 2.82840.0019.00 ± 14.08714.67 ± 9.50411.33 ± 9.2064.00 ± 3.464
SecondaryAbsolute Values of CDASI Damage Score at All Scheduled Timepoints Through Week 12 (All Stages)

The Damage Score (DS) was calculated as a sum of the total poilkiloderma score (POLS), total calcinosis score (CALS) and Gotorn's hands damage score (GHDS). The POLS characterizes specific dispigmentation in the particulal area and calcinosis score characterizes calcification of the skin in the particular area. The POLS and the CALS are summed up over 15 individual areas in the body and each of them has range 0-15. The GHDS has the range 0-2 so that the DS has the range 0-32. Higher scores indicate greater disease severity.

Time frame:
Baseline, Week 1, Week 4, Week 8 and Week 12
Reported as:
Mean · Units on a scale
Absolute Values of CDASI Damage Score at All Scheduled Timepoints Through Week 12 (All Stages)
Units on a scale(Stage 1) PlaceboPF-06823859 600 mg IV (Stage 1)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12
Baseline4.30 ± 5.3975.50 ± 3.9013.004.20 ± 3.7017.00 ± 1.7327.50 ± 4.9507.004.70 ± 4.3737.00 ± 3.0005.56 ± 6.0442.00 ± 1.871
Week 14.90 ± 5.0215.41 ± 4.1594.003.80 ± 3.3476.33 ± 3.2156.00 ± 7.0717.003.90 ± 3.5424.67 ± 2.8876.00 ± 5.8091.89 ± 1.764
Week 45.11 ± 5.2785.23 ± 3.3374.003.00 ± 2.4499.00 ± 1.7327.00 ± 5.6577.004.40 ± 4.2486.33 ± 1.5285.22 ± 4.6311.56 ± 2.297
Week 85.89 ± 5.2315.00 ± 4.4275.004.40 ± 2.8818.33 ± 0.5775.50 ± 3.5367.003.70 ± 3.9454.67 ± 3.2155.11 ± 4.8591.00 ± 1.118
Week 126.33 ± 5.6795.05 ± 3.9056.003.60 ± 3.2866.33 ± 1.5284.50 ± 4.9507.003.10 ± 4.3585.00 ± 1.0005.22 ± 5.0191.33 ± 1.581
SecondaryAbsolute Values for Total Improvement Score (TIS) at Week 12 and Intermediate Scheduled Time Points (Stage 3)

The TIS was the sum of all 6 improvement scores where higher score indicates worse status (PhGA \[from the MDAAT, 0-20 scale\], PtGA \[0-10 scale\], MMT \[0-35 scale\], HAQ-DI \[0-10 scale\], muscle enzymes \[0-7.5 scale\], and extramuscular global assessment \[0-20 scale\]) associated with the change in each core set measure. A total improvement score between 0 and 100 corresponded to the degree of improvement, with higher scores corresponding to a greater degree of improvement: of ≥20 represented minimal improvement, a score of ≥40 represented moderate improvement, and a score of ≥60 represented major improvement.

Time frame:
Week 4, Week 8 and Week 12
Reported as:
Least squares mean · Units on a scale
Absolute Values for Total Improvement Score (TIS) at Week 12 and Intermediate Scheduled Time Points (Stage 3)
Units on a scalePlacebo (Stage 3)PF-06823859 600 mg IV (Stage 3)
Week 425.83 (13.15 to 38.52)36.67 (23.98 to 49.35)
Week 836.67 (23.38 to 49.95)49.17 (35.88 to 62.45)
Week 1236.94 (21.93 to 51.96)56.39 (41.38 to 71.40)
Statistical analysis
  • Placebo (Stage 3) vs PF-06823859 600 mg IV (Stage 3) · Mixed Models Analysis · p = 0.1537 · Least squares mean difference: 10.83 · 90% CI -7.10 to 28.77
  • Placebo (Stage 3) vs PF-06823859 600 mg IV (Stage 3) · Mixed Models Analysis · p = 0.1312 · Least squares mean difference: 12.50 · 90% CI -6.29 to 31.29
  • Placebo (Stage 3) vs PF-06823859 600 mg IV (Stage 3) · Mixed Models Analysis · p = 0.0647 · Least squares mean difference: 19.44 · 90% CI -1.79 to 40.68
SecondaryChange From Baseline in the Core Set Measures (CSM) of the TIS (Global Disease Activity [PhGA] and Extramuscular Global Assessment [EmGA]) (Stage 3)

PhGA: assessment of the severity of disease by the physician. The physician used the visual analog scale and put a mark on 0 cm (best) -10 cm (worst) scale where higher score indicated worse status. EmGA: overall evaluation of disease activity in all extramuscular systems using visual analog scale 0 cm (best) -10 cm (worst) scale where higher score indicated worse status.

Time frame:
Baseline, Week 4, Week 8 and Week 12
Reported as:
Least squares mean · Centimeter (cm)
Change From Baseline in the Core Set Measures (CSM) of the TIS (Global Disease Activity [PhGA] and Extramuscular Global Assessment [EmGA]) (Stage 3)
Centimeter (cm)Placebo (Stage 3)PF-06823859 600 mg IV (Stage 3)
PhGA Week 4-1.00 (-1.89 to -0.11)-1.68 (-2.57 to -0.79)
PhGA Week 8-1.65 (-2.80 to -0.51)-2.76 (-3.90 to -1.61)
PhGA Week 12-2.05 (-3.56 to -0.55)-3.40 (-4.90 to -1.90)
Extramuscular Global Assessment Week 4-1.02 (-2.07 to 0.03)-1.55 (-2.60 to -0.49)
Extramuscular Global Assessment Week 8-1.91 (-2.80 to -1.01)-2.48 (-3.38 to -1.58)
Extramuscular Global Assessment Week 12-1.59 (-2.64 to -0.53)-2.81 (-3.87 to -1.76)
SecondaryChange From Baseline in the CSM of the TIS (PtGA) (Stage 3)

PtGA: assessment of the severity of disease by the participant/participant's guardian, using a visual analog scale from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.

Time frame:
Baseline, Week 4, Week 8 and Week 12
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline in the CSM of the TIS (PtGA) (Stage 3)
Millimeter (mm)Placebo (Stage 3)PF-06823859 600 mg IV (Stage 3)
PtGA Week 4-18.29 (-31.78 to -4.79)-17.88 (-30.75 to -5.00)
PtGA Week 8-16.81 (-29.88 to -3.73)-32.60 (-45.85 to -19.35)
PtGA Week 12-14.04 (-25.91 to -2.17)-43.81 (-55.68 to -31.95)
SecondaryChange From Baseline in the CSM of the TIS (MMT8 and HAQ01-HAQ-DI) (Stage 3)

Manual Muscle Testing-8 designated muscle groups (MMT-8): was a set of 8 designated muscles tested unilaterally generally on right side (left side used unless right side cannot be used). Potential score range was from 0 to 80, where higher scores denoted better health status. HAQ-DI: contained eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.

Time frame:
Week 4, Week 8 and Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the CSM of the TIS (MMT8 and HAQ01-HAQ-DI) (Stage 3)
Units on a scalePlacebo (Stage 3)PF-06823859 600 mg IV (Stage 3)
MMT8 - Derived Week 47.76 (1.37 to 14.16)8.24 (1.84 to 14.63)
MMT8 - Derived Week 812.14 (4.60 to 19.68)15.24 (7.70 to 22.78)
MMT8 - Derived Week 1211.65 (2.29 to 21.01)21.24 (11.87 to 30.60)
HAQ01-HAQ-DI Week 4-0.03 (-0.24 to 0.18)-0.20 (-0.39 to 0.00)
HAQ01-HAQ-DI Week 80.00 (-0.28 to 0.28)-0.38 (-0.64 to -0.11)
HAQ01-HAQ-DI Week 12-0.06 (-0.40 to 0.28)-0.52 (-0.84 to -0.19)
SecondaryChange From Baseline in the CSM of the TIS (Aldolase and Creatine Kinase) (Stage 3)

The LS mean (with 90% CI) of CSM of the TIS (aldolase and creatine kinase) at weeks 4, 8, 12 were presented.

Time frame:
Baseline, Week 4, Week 8 and Week 12
Reported as:
Least squares mean · Units per litre (U/L)
Change From Baseline in the CSM of the TIS (Aldolase and Creatine Kinase) (Stage 3)
Units per litre (U/L)Placebo (Stage 3)PF-06823859 600 mg IV (Stage 3)
Aldolase Week 4-0.19 (-1.34 to 0.96)-3.09 (-4.25 to -1.92)
Aldolase Week 8-1.31 (-2.45 to -0.16)-3.57 (-4.74 to -2.40)
Aldolase Week 12-0.66 (-2.18 to 0.86)-3.20 (-4.76 to -1.64)
Creatine Kinase Week 4-37.96 (-119.16 to 43.24)-157.48 (-238.68 to -76.28)
Creatine Kinase Week 8-70.96 (-137.03 to -4.90)-175.93 (-241.99 to -109.86)
Creatine Kinase ) Week 12-39.85 (-125.71 to 46.01)-185.77 (-273.92 to -97.62)

Adverse events

Collected over Up to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/45 (2.2%)3/45 (6.7%)22/45 (48.9%)
PF-06823859 150 mg IV0/17 (0%)0/17 (0%)13/17 (76.5%)
PF-06823859 600 mg IV1/47 (2.1%)4/47 (8.5%)18/47 (38.3%)
Total1/75 (1.3%)5/75 (6.7%)45/75 (60%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-06823859 150 mg IVPF-06823859 600 mg IVTotal
CytopeniaBlood and lymphatic system disorders1/450/170/471/75
LeukopeniaBlood and lymphatic system disorders1/450/171/471/75
Ocular icterusHepatobiliary disorders1/450/170/471/75
Haemophagocytic lymphohistiocytosisImmune system disorders1/450/170/471/75
Humerus fractureInjury, poisoning and procedural complications1/450/171/471/75
Blood bilirubin increasedInvestigations1/450/170/471/75
Hepatic enzyme increasedInvestigations1/450/170/471/75
Central nervous system lesionNervous system disorders1/450/170/471/75
Colitis microscopicGastrointestinal disorders0/450/171/471/75
OsteoarthritisMusculoskeletal and connective tissue disorders0/450/171/471/75
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboPF-06823859 150 mg IVPF-06823859 600 mg IVTotal
HeadacheNervous system disorders7/453/176/4715/75
ArthralgiaMusculoskeletal and connective tissue disorders1/452/173/475/75
PruritusSkin and subcutaneous tissue disorders5/451/171/476/75
FatigueGeneral disorders4/451/171/476/75
SARS-CoV-2 test positiveInvestigations4/450/171/474/75
Upper respiratory tract infectionInfections and infestations1/450/174/475/75
NauseaGastrointestinal disorders2/450/173/475/75
SinusitisInfections and infestations3/451/170/474/75
DiarrhoeaGastrointestinal disorders0/451/173/474/75
Iron deficiency anaemiaBlood and lymphatic system disorders0/451/170/471/75

Baseline characteristics

The safety analysis population included all participants who had received at least 1 dose of study drug or placebo.

Age, Continuous
Age, Continuous(years)(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12Total
Mean50.20 ± 14.05454.41 ± 13.15442.0051.60 ± 15.72645.67 ± 23.71464.00 ± 1.4144453.90 ± 10.99947.00 ± 13.11547.44 ± 12.12642.44 ± 16.69750.63 ± 13.793
Age, Customized
Age, Customized(Participants)(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12Total
18-64 Years81814211838862
65-84 Years2401110201113
>=85 Years000000000000
Sex: Female, Male
Sex: Female, Male(Participants)(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12Total
Female920153211026766
Male120000001329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12Total
Hispanic or Latino2210100113213
Not Hispanic or Latino82005221926762
Unknown or Not Reported000000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)(Stage 1) Placebo(Stage 1) PF-06823859 600 mg Intravenous (IV)(Stage 2) Placebo(Stage 2) PF-06823859 150 mg IV(Stage 2) PF-06823859 600 mg IV(Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12(Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12(Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12(Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12(Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12Total
White92015321938869
Black or African American000000000000
Asian000000010102
American Indian or Alaska Native000000000000
Native Hawaiian or Other Pacific Islander000000000000
Other000000000000
Multiracial100000000001
Not reported020000000013
08

Study locations

41 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Arizona Research Pharmacy
    Phoenix, Arizona 85054, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Attune Health Research Inc.
    Beverly Hills, California 90211, United States
  • Freidenrich Center for Translational Research at Stanford University
    Palo Alto, California 94304, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • University Of Miami Hospital
    Miami, Florida 33125, United States
  • University of Miami Hospital Clinical Translational Research Site (Infusion site)
    Miami, Florida 33136, United States
  • KU Clinical Research Center - Clinical and Translational Science Unit (CTSU)
    Fairway, Kansas 66205, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224-6821, United States
  • Brigham and Women's Hospital - ACC
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital - CTC
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital - CTH
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Research Unit (CRU)
    Minneapolis, Minnesota 55455, United States
  • Department of Medicine Division of Rheumatic and Autoimmune Disease
    Minneapolis, Minnesota 55455, United States
  • Lillehei Clinical Research Unit (LCRU)
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Health Rheumatology Clinic
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota, Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • Center for Outpatient Health
    Saint Louis, Missouri 63108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • NYU Langone Health Clinical Research Center
    New York, New York 10016, United States
  • Mount Sinai Doctors Dermatology
    New York, New York 10028, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • OHSU, Center for Health and Healing CHH2
    Portland, Oregon 97239, United States
  • Oregon Clinical & Translational Research Institute
    Portland, Oregon 97239, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9191, United States
  • University of Utah MidValley Dermatology
    Murray, Utah 84107, United States
  • Center for Clinical & Translational Science
    Salt Lake City, Utah 84108, United States
  • Universitaetsklinikum Tuebingen
    Tuebingen, 72076, Germany
  • University of Debrecen
    Debrecen, Hajdú-bihar H-4032, Hungary
  • Nova Reuma spolka partnerska
    Bialystok, 15-707, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Quiron Infanta Luisa
    Sevilla, 41010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in May 2022, 52 months.

Results were first posted in Sep 2023, 1 year 3 months after primary completion.

Of 19 phase 2 interventional studies under Dermatomyositis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jun 9, 2017
StartActual
Jan 23, 2018
Primary completionActual
May 27, 2022
CompletionActual
Nov 28, 2022
Results first posted
Sep 14, 2023
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03181893
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Jan 23, 2018
Primary completion
May 27, 2022
Completion
Nov 28, 2022
Results posted
Sep 14, 2023
Last update
Sep 14, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazukibart

Start the discussion